/LUNG
LUNG Stock - Pulmonx Corporation
Healthcare|Medical - DevicesNASDAQ
$2.60+3.17%
+$0.08 (+3.17%) • Dec 19
77
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.46
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+53.8%upside
Target: $4.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for LUNG
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.57 – $2.63
TARGET (TP)$4.00
STOP LOSS$2.39
RISK/REWARD1:6.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.22
52W High$9.37
52W Low$1.31
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $83.79M | $68.67M | $53.66M | $48.42M | $32.73M |
| Gross Profit | $62.00M | $50.75M | $39.87M | $35.63M | $21.20M |
| Gross Margin | 74.0% | 73.9% | 74.3% | 73.6% | 64.8% |
| Operating Income | $-57,704,000 | $-61,935,000 | $-58,637,000 | $-47,304,000 | $-32,332,000 |
| Net Income | $-56,394,000 | $-60,843,000 | $-58,923,000 | $-48,661,000 | $-32,231,000 |
| Net Margin | -67.3% | -88.6% | -109.8% | -100.5% | -98.5% |
| EPS | $-1.44 | $-1.60 | $-1.59 | $-1.35 | $-0.90 |
Company Overview
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
44%
Hold / Neutral
4
44%
Sell / Underperform
1
11%
Analyst Consensus🔴 Bearish
4 Bullish5 Neutral/Bearish
Price Targets
$12
Average Target
↑ 373.1% Upside
Now
$3
Low
$12
Average
$19
High
Based on 10 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 31st 2025 | Piper Sandler | Downgrade | Neutral | $2.5 |
| March 10th 2025 | D. Boral Capital | Initiation | Buy | $17 |
| December 11th 2024 | Citigroup | Downgrade | Neutral | $7.5← $17 |
| June 4th 2024 | Lake Street | Initiation | Buy | $12 |
| February 23rd 2024 | Wells Fargo | Downgrade | Equal Weight | $14← $16 |
| September 5th 2023 | Craig Hallum | Initiation | Buy | $18 |
| February 27th 2023 | Wells Fargo | Upgrade | Overweight | $15← $10 |
| January 3rd 2023 | BofA Securities | Downgrade | Underperform | $8 |
| December 12th 2022 | Citigroup | Upgrade | Buy | $10← $14 |
| July 11th 2022 | Citigroup | Downgrade | Neutral | $19← $23 |
Earnings History & Surprises
LUNGBeat Rate
83%
Last 18 quarters
Avg Surprise
+8.0%
EPS vs Estimate
Beats / Misses
15/1
2 met exactly
Latest EPS
$-0.34
Q4 2025
EPS Surprise History
Q1 24
+7.7%
$-0.36vs$-0.39
Q2 24
+16.3%
$-0.36vs$-0.43
Q3 24
+4.9%
$-0.39vs$-0.41
Q4 24
+16.3%
$-0.36vs$-0.43
Q1 25
+26.7%
$-0.33vs$-0.45
Q2 25
+2.7%
$-0.36vs$-0.37
Q3 25
+5.0%
$-0.38vs$-0.40
Q4 25
+15.0%
$-0.34vs$-0.40
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 28, 2026 | — | — | — | — |
Q1 2026 | Feb 18, 2026 | $-0.39 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.40 | $-0.34 | +15.0% | ✓ BEAT |
Q3 2025 | Jul 30, 2025 | $-0.40 | $-0.38 | +5.0% | ✓ BEAT |
Q2 2025 | Apr 30, 2025 | $-0.37 | $-0.36 | +2.7% | ✓ BEAT |
Q1 2025 | Feb 19, 2025 | $-0.45 | $-0.33 | +26.7% | ✓ BEAT |
Q4 2024 | Oct 30, 2024 | $-0.43 | $-0.36 | +16.3% | ✓ BEAT |
Q3 2024 | Jul 31, 2024 | $-0.41 | $-0.39 | +4.9% | ✓ BEAT |
Q2 2024 | May 1, 2024 | $-0.43 | $-0.36 | +16.3% | ✓ BEAT |
Q1 2024 | Feb 21, 2024 | $-0.39 | $-0.36 | +7.7% | ✓ BEAT |
Q4 2023 | Oct 30, 2023 | $-0.45 | $-0.39 | +13.3% | ✓ BEAT |
Q3 2023 | Aug 2, 2023 | $-0.43 | $-0.43 | 0.0% | = MET |
Q2 2023 | May 2, 2023 | $-0.43 | $-0.42 | +2.3% | ✓ BEAT |
Q1 2023 | Feb 22, 2023 | $-0.41 | $-0.38 | +7.3% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-0.40 | $-0.38 | +5.0% | ✓ BEAT |
Q3 2022 | Aug 2, 2022 | $-0.41 | $-0.40 | +2.4% | ✓ BEAT |
Q2 2022 | May 3, 2022 | $-0.37 | $-0.43 | -16.2% | ✗ MISS |
Q1 2022 | Feb 23, 2022 | $-0.35 | $-0.35 | 0.0% | = MET |
Q4 2021 | Nov 2, 2021 | $-0.37 | $-0.28 | +24.3% | ✓ BEAT |
Q3 2021 | Aug 3, 2021 | $-0.38 | $-0.34 | +10.5% | ✓ BEAT |
Latest News
D. Boral Capital Maintains Buy on Pulmonx, Maintains $14 Price Target
📈 PositiveBenzinga•Nov 13, 2025, 01:59 PM
Pulmonx Lowers FY2025 Sales Guidance from $90.000M-$92.000M to $89.000M-$90.000M vs $90.695M Est
📉 NegativeBenzinga•Nov 12, 2025, 09:06 PM
Pulmonx Q3 EPS $(0.34) Beats $(0.42) Estimate, Sales $21.502M Beat $20.868M Estimate
📈 PositiveBenzinga•Nov 12, 2025, 09:06 PM
Pulmonx shares are trading higher after the company said preliminary Q3 revenue is expected to be about $21.5 million.
📈 PositiveBenzinga•Oct 28, 2025, 04:40 PM
Lake Street Maintains Buy on Pulmonx, Lowers Price Target to $4
➖ NeutralBenzinga•Oct 28, 2025, 04:28 PM
D. Boral Capital Maintains Buy on Pulmonx, Lowers Price Target to $14
➖ NeutralBenzinga•Oct 28, 2025, 11:12 AM
Pulmonx Preliminary, Unaudited Q3 2025 Revenue Expected To Be ~$21.5M
➖ NeutralBenzinga•Oct 27, 2025, 08:22 PM
Pulmonx Reappoints Glen French As President And CEO And Appoints Derrick Sung COO and CFO
➖ NeutralBenzinga•Oct 27, 2025, 08:18 PM
D. Boral Capital Maintains Buy on Pulmonx, Maintains $16 Price Target
📈 PositiveBenzinga•Sep 8, 2025, 11:17 AM
Jaeger And Pulmonx Announce Strategic Partnership To Integrate Data Qualification Capabilities Into SentrySuite
📈 PositiveBenzinga•Aug 27, 2025, 01:13 PM
Pulmonx slumps as Piper Sandler downgrades despite Q2 beat
📉 NegativeSeeking Alpha•Jul 31, 2025, 07:28 PM
Frequently Asked Questions about LUNG
What is LUNG's current stock price?
Pulmonx Corporation (LUNG) is currently trading at $2.60 per share. The stock has moved +3.17% today.
What is the analyst price target for LUNG?
The average analyst price target for LUNG is $4.00, based on 1 analyst.
What sector is Pulmonx Corporation in?
Pulmonx Corporation operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is LUNG's market cap?
Pulmonx Corporation has a market capitalization of $0.11 billion, making it a small-cap company.
Does LUNG pay dividends?
No, Pulmonx Corporation does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACRV
Acrivon Therapeutics, Inc. Common Stock
$2.16
Mkt Cap: $0.1B
ASRT
Assertio Holdings, Inc.
$0.72
Mkt Cap: $0.1B
EDAP
Edap Tms S.a.
$2.94
Mkt Cap: $0.1B
HYPR
Hyperfine, Inc.
$1.10
Mkt Cap: $0.1B
IMUX
Immunic, Inc.
$0.57
Mkt Cap: $0.1B
PMVP
PMV Pharmaceuticals, Inc.
$1.24
Mkt Cap: $0.1B
RLMD
Relmada Therapeutics, Inc.
$4.35
Mkt Cap: $0.3B
TCRX
TScan Therapeutics, Inc.
$0.90
Mkt Cap: $0.1B
TELA
TELA Bio, Inc.
$1.13
Mkt Cap: $0.0B
VXRT
Vaxart, Inc.
$0.35
Mkt Cap: $0.1B
Explore stocks similar to LUNG for comparison